|Bid||71.31 x 1100|
|Ask||71.49 x 1800|
|Day's Range||70.82 - 79.30|
|52 Week Range||13.00 - 126.90|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||102.67|
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Barclays 2021 Global Healthcare Conference on Thursday, March 11, 2021 at 2:25 p.m. ET. The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archived for 60 days following the presentation. About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. For more information, visit www.beamtx.com. Contacts: Investors:Chelcie ListerTHRUST Strategic Communicationschelcie@thrustsc.com Media:Dan Budwick1ABdan@1abmedia.com
Beam Therapeutics announced it had acquired Guide Therapeutics, a maker of components for genetic medicines — and Beam stock tumbled. Broadly, biotech stocks were under pressure.
Beam Therapeutics Inc (NASDAQ: BEAM) acquires Guide Therapeutics (GuideTx), a developer of nonviral drug delivery vehicles for genetic medicines, in an all-stock deal for $120 million upfront. GuideTx shareholders could also yield up to $320 million more in milestone payments. Beam is betting that adding GuideTx’s lipid nanoparticle (LNP) drug delivery vehicles to the mix will boost its genetic medicines’ reach into new tissues and disease areas. GuideTx’s LNP screening technology tags nanoparticles with DNA barcodes allows hundreds of nanoparticles to be screened in one experiment, in a single animal. So far, GuideTx has identified a library of lipids and lipid formulations that could ramp up the development of gene editing treatments to tissues other than the liver. Price Action: BEAM is down 14.4% at $94.56 in market trading hours on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaProgenity Secures M Via Equity Issued At 5% DiscountAkers Biosciences' Proposed Partner MyMD's Lead Candidate Inhibits Fibrotic Diseases-Associated Biomarkers© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.